Haemonetics Corporation
HAE Healthcare Medical Devices
Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HAE
Haemonetics Corporation (HAE) P/E ratio
As of 16 October 2026, Haemonetics Corporation (HAE) trades at a P/E ratio of 57.7×. Over the past ten years it has ranged from 0.0× (March 2018) to 737× (November 2017); the current reading is higher than 58% of that period. That is above the Medical Devices industry median of 23.2× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 27.8× | 45.92% |
| FY2025 | 19.0× | (48.61%) |
| FY2024 | 37.0× | 0.68% |
| FY2023 | 36.8× | (51.13%) |
| FY2022 | 75.3× | 5.76% |
| FY2021 | 71.2× | 7.82% |
| FY2020 | 66.0× | (22.79%) |
| FY2019 | 85.5× | 1.87% |
| FY2018 | 83.9× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 36.6× | 31.78% |
| Mar 2026 | 27.8× | 26.43% |
| Dec 2025 | 22.0× | 54.98% |
| Sep 2025 | 14.2× | (37.52%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BRKR Bruker Corporation compare | n/m |
| IRTC iRhythm Holdings, Inc. compare | n/m |
| GKOS Glaukos Corporation compare | n/m |
| LIVN LivaNova PLC compare | 22.5× |
| PODD Insulet Corporation compare | 26.4× |
| ITGR Integer Holdings Corporation compare | 34.3× |
| BIO Bio-Rad Laboratories, Inc. compare | 42.5× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 43.7× |
| HAE Haemonetics Corporation | 57.7× |
| Medical Devices industry median | 23.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)